Artificial intelligence performance supported chest scanner to assess radiological improvement in patients with COVID-19 pneumonia: pirfenidon vs corticosteroid comparison – Acat – – International Journal of Clinical Practice


Our objective was to study the effect of short-term pirfenidone treatment on prolonged COVID-19 pneumonia.


Hospital records of patients hospitalized with a diagnosis of critical COVID-19 pneumonia between November 2020 and March 2021 have been retrospectively reviewed. Chest CT images taken both before treatment and 2 months after treatment, demographic characteristics and laboratory parameters of patients receiving pirfenidone + methylprednisolone (n = 13) and only methylprednisolones (n = 9) were recorded. Lung function tests were done after the second month of treatment. CT involvement rates were determined by machine learning.


A total of 22 patients, of whom 13 (59.1%) used methylprednisolone + pirfenidone and 9 (40.9%) used only methylprednisolone were included. When patients’ blood gas parameters and lung function tests were compared at the end of the second month, it was found that FEV1, FEV1%, CVF, and CVF% were statistically significantly higher in the methylprednisolone group. + pirfenidone compared to the methylprednisolone group (p = 0.025, p = 0.012, p = 0.026 and p = 0.017, respectively). When the rates of change from CT scans at diagnosis and at month 2 of treatment were examined, it was found that the involvement rates in the methylprednisolone + pirfenidone group were statistically significantly reduced (p <0.001).


Antifibrotic agents can reduce fibrosis that may develop in the future. These can also help reduce the dose and / or the non-use strategy for methylprednisolone treatment, which has many side effects. Further large series and randomized controlled studies are needed on this subject.

Leave a Comment